Indinavir
- Generic Name
- Indinavir
- Brand Names
- Crixivan
- Drug Type
- Small Molecule
- Chemical Formula
- C36H47N5O4
- CAS Number
- 150378-17-9
- Unique Ingredient Identifier
- 9MG78X43ZT
- Background
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
- Indication
Indinavir is an antiretroviral drug for the treatment of HIV infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
- Conditions
- HIV Infections
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00005762
- Locations
- 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 200
- Registration Number
- NCT00000870
- Locations
- 🇺🇸
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1750
- Registration Number
- NCT00000841
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 1300
- Registration Number
- NCT00000859
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸Baltimore TRIALS, Baltimore, Maryland, United States
The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 1900
- Registration Number
- NCT00000861
- Locations
- 🇺🇸
Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States
🇺🇸Veterans Administration Med Ctr / Regional AIDS Program, Washington, District of Columbia, United States
🇺🇸North Jersey Community Research Initiative, Newark, New Jersey, United States
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 94
- Registration Number
- NCT00001095
- Locations
- 🇺🇸
St Louis Regional Hosp / St Louis Regional Med Ctr, Saint Louis, Missouri, United States
🇺🇸Univ of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 29
- Registration Number
- NCT00012519
- Locations
- 🇺🇸
Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States
🇺🇸Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
🇺🇸Metropolitan Hosp. Ctr., New York, New York, United States
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 24
- Registration Number
- NCT00000901
- Locations
- 🇺🇸
UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States
🇺🇸Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 288
- Registration Number
- NCT00001119
- Locations
- 🇺🇸
Seattle HIVNET, Seattle, Washington, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.